Residual risk prediction in anticoagulated patients with atrial fibrillation using machine learning: A report from the GLORIA-AF registry phase II/III.

IF 4.4 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Yang Liu, Yang Chen, Ivan Olier, Sandra Ortega-Martorell, Bi Huang, Hironori Ishiguchi, Ho Man Lam, Kui Hong, Menno V Huisman, Gregory Y H Lip
{"title":"Residual risk prediction in anticoagulated patients with atrial fibrillation using machine learning: A report from the GLORIA-AF registry phase II/III.","authors":"Yang Liu, Yang Chen, Ivan Olier, Sandra Ortega-Martorell, Bi Huang, Hironori Ishiguchi, Ho Man Lam, Kui Hong, Menno V Huisman, Gregory Y H Lip","doi":"10.1111/eci.14371","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although oral anticoagulation decreases the risk of thromboembolism in patients with atrial fibrillation (AF), a residual risk of thrombotic events still exists. This study aimed to construct machine learning (ML) models to predict the residual risk in these patients.</p><p><strong>Methods: </strong>Patients with newly diagnosed non-valvular AF were collected from the Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. To predict the residual risk of the composite outcome of thrombotic events (defined as ischemic stroke, systemic embolism, transient ischemic attack and myocardial infarction), we constructed four prediction models using the logistic regression (LR), random forest, light gradient boosting machine and extreme gradient boosting machine ML algorithms. Performance was mainly evaluated by area under the receiver-operating characteristic curve (AUC), g-means and F1 scores. Feature importance was evaluated by SHapley Additive exPlanations.</p><p><strong>Results: </strong>15,829 AF patients (70.33 ± 9.94 years old, 55% male) taking oral anticoagulation were included in our study, and 641 (4.0%) had residual risk, sustaining thrombotic events. In the test set, LR had the best performance with higher AUC trend of 0.712. RF has highest g-means of 0.295 and F1 score of 0.249. This was superior when compared with the CHA<sub>2</sub>DS<sub>2</sub>-VA score (AUC 0.698) and 2MACE score (AUC 0.696). Age, history of TE or MI, OAC discontinuation, eGFR and sex were identified as the top five factors associated with residual risk.</p><p><strong>Conclusion: </strong>ML algorithms can improve the prediction of residual risk of anticoagulated AF patients compared to clinical risk factor-based scores.</p>","PeriodicalId":12013,"journal":{"name":"European Journal of Clinical Investigation","volume":" ","pages":"e14371"},"PeriodicalIF":4.4000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/eci.14371","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Although oral anticoagulation decreases the risk of thromboembolism in patients with atrial fibrillation (AF), a residual risk of thrombotic events still exists. This study aimed to construct machine learning (ML) models to predict the residual risk in these patients.

Methods: Patients with newly diagnosed non-valvular AF were collected from the Global Registry on Long-Term Oral Anti-Thrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. To predict the residual risk of the composite outcome of thrombotic events (defined as ischemic stroke, systemic embolism, transient ischemic attack and myocardial infarction), we constructed four prediction models using the logistic regression (LR), random forest, light gradient boosting machine and extreme gradient boosting machine ML algorithms. Performance was mainly evaluated by area under the receiver-operating characteristic curve (AUC), g-means and F1 scores. Feature importance was evaluated by SHapley Additive exPlanations.

Results: 15,829 AF patients (70.33 ± 9.94 years old, 55% male) taking oral anticoagulation were included in our study, and 641 (4.0%) had residual risk, sustaining thrombotic events. In the test set, LR had the best performance with higher AUC trend of 0.712. RF has highest g-means of 0.295 and F1 score of 0.249. This was superior when compared with the CHA2DS2-VA score (AUC 0.698) and 2MACE score (AUC 0.696). Age, history of TE or MI, OAC discontinuation, eGFR and sex were identified as the top five factors associated with residual risk.

Conclusion: ML algorithms can improve the prediction of residual risk of anticoagulated AF patients compared to clinical risk factor-based scores.

使用机器学习预测抗凝房颤患者的剩余风险:来自GLORIA-AF登记II/III期的报告
背景:虽然口服抗凝降低心房颤动(AF)患者血栓栓塞的风险,但血栓事件的残余风险仍然存在。本研究旨在构建机器学习(ML)模型来预测这些患者的剩余风险。方法:从全球房颤患者长期口服抗血栓治疗登记中心(GLORIA-AF)收集新诊断的非瓣膜性房颤患者。为了预测血栓事件(定义为缺血性卒中、全身栓塞、短暂性缺血性发作和心肌梗死)复合结局的剩余风险,我们使用逻辑回归(LR)、随机森林、光梯度增强机和极端梯度增强机ML算法构建了四个预测模型。主要通过受试者工作特征曲线下面积(AUC)、g-means和F1评分来评价。特征重要性通过SHapley加性解释进行评估。结果:15829例口服抗凝的房颤患者(70.33±9.94岁,男性55%)纳入我们的研究,其中641例(4.0%)存在持续血栓形成事件的残留风险。在测试集中,LR表现最好,AUC趋势较高,为0.712。RF的最高g均值为0.295,F1得分为0.249。与CHA2DS2-VA评分(AUC 0.698)和2MACE评分(AUC 0.696)相比,这是优越的。年龄、TE或MI病史、OAC停药、eGFR和性别被确定为与剩余风险相关的前五大因素。结论:与基于临床危险因素评分相比,ML算法可以提高对抗凝房颤患者剩余风险的预测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.50
自引率
3.60%
发文量
192
审稿时长
1 months
期刊介绍: EJCI considers any original contribution from the most sophisticated basic molecular sciences to applied clinical and translational research and evidence-based medicine across a broad range of subspecialties. The EJCI publishes reports of high-quality research that pertain to the genetic, molecular, cellular, or physiological basis of human biology and disease, as well as research that addresses prevalence, diagnosis, course, treatment, and prevention of disease. We are primarily interested in studies directly pertinent to humans, but submission of robust in vitro and animal work is also encouraged. Interdisciplinary work and research using innovative methods and combinations of laboratory, clinical, and epidemiological methodologies and techniques is of great interest to the journal. Several categories of manuscripts (for detailed description see below) are considered: editorials, original articles (also including randomized clinical trials, systematic reviews and meta-analyses), reviews (narrative reviews), opinion articles (including debates, perspectives and commentaries); and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信